Amy S. Ruppert
YOU?
Author Swipe
View article: BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
PURPOSE BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (Ben…
View article: Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
PURPOSE Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BT…
View article: Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations
Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations Open
Acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplication ( FLT3 -ITD) experience shorter disease-free survival and high relapse rates even with FLT3 inhibitor therapy. One of the main mechanisms for…
View article: Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial Open
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (rev…
View article: Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy Open
Clinical bleeding events are reported here from 773 patients with B‐cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of ant…
View article: Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101 Open
Although it is evident that standard-dose whole-brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We per…
View article: Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL Open
A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The ini…
View article: P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Covalent Bruton tyrosine kinase inhibitors (BTKi) have been an important advancement of Waldenström macroglobulinemia (WM) treatment, but they are non-curative…
View article: P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Though covalent Bruton tyrosine kinase inhibitors (BTKi) greatly improved outcomes in patients with B-cell malignancies, they are associated with an increased …
View article: Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories Open
Next-generation sequencing (NGS) to identify pathogenic mutations is an integral part of acute myeloid leukemia (AML) therapeutic decision-making. The concordance in identifying pathogenic mutations among different NGS platforms at differe…
View article: Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia Open
In this trial, pirtobrutinib showed efficacy in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor. The most common adverse events were infections, bleeding, and neutropenia. (Funded by Loxo Oncology; BRU…
View article: Entospletinib with decitabine in acute myeloid leukemia with mutant <i>TP53</i> or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Entospletinib with decitabine in acute myeloid leukemia with mutant <i>TP53</i> or complex karyotype: A phase 2 substudy of the Beat AML Master Trial Open
Background Patients with acute myeloid leukemia (AML) who have tumor protein p53 ( TP53 ) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors evaluated the efficacy of entospletini…
View article: Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
Purpose: Flavopiridol, the first clinically evaluated cyclin-dependent kinase inhibitor, shows activity in patients with refractory chronic lymphocytic leukemia, but prevalent and unpredictable tumor lysis syndrome (TLS) presents a major b…
View article: Supplementary Table S1 from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α
Supplementary Table S1 from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α Open
Supplementary Table S1 from Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α
View article: Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 51 KB
View article: Supplementary Table S1 from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α
Supplementary Table S1 from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α Open
Supplementary Table S1 from Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α
View article: Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 79 KB, Supplementary Table 1. Patient Characteristics Supplementary Table 2. Summary of drop-outs in Cycle 1
View article: Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study Open
Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
View article: Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 51 KB
View article: Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 255 KB, Figure 1. Flavopiridol conditional weighted residuals vs. time with a smoothed loess line. Figure 2. Flavopiridol conditional weighted residuals vs. population predicted values with a smoothed loess line. Figure 3. Visua…
View article: Data from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α
Data from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α Open
Purpose: The precise molecular targets of IFN-α therapy in the context of malignant melanoma are unknown but seem to involve signal transducers and activators of transcription 1 signal transduction within host immune effector cells. We hyp…
View article: Data from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α
Data from Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN-α Open
Purpose: The precise molecular targets of IFN-α therapy in the context of malignant melanoma are unknown but seem to involve signal transducers and activators of transcription 1 signal transduction within host immune effector cells. We hyp…
View article: Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study Open
Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
View article: Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study Open
Purpose:Dual blockade of Bruton's tyrosine kinase with ibrutinib and selinexor has potential to deepen responses for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).Patients and Methods:In this phase I study…
View article: Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 255 KB, Figure 1. Flavopiridol conditional weighted residuals vs. time with a smoothed loess line. Figure 2. Flavopiridol conditional weighted residuals vs. population predicted values with a smoothed loess line. Figure 3. Visua…
View article: Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study Open
Purpose:Dual blockade of Bruton's tyrosine kinase with ibrutinib and selinexor has potential to deepen responses for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).Patients and Methods:In this phase I study…
View article: Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 79 KB, Supplementary Table 1. Patient Characteristics Supplementary Table 2. Summary of drop-outs in Cycle 1
View article: Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
Purpose: Flavopiridol, the first clinically evaluated cyclin-dependent kinase inhibitor, shows activity in patients with refractory chronic lymphocytic leukemia, but prevalent and unpredictable tumor lysis syndrome (TLS) presents a major b…